AvTech Laboratories and Chimera Biotec sign agreement that combines Chimera's ultra-high sensitive immunoassay technology, Imperacer, with AvTech's expertise in state-of-the-art analytical service
AvTech will serve as the primary provider of Imperacer in the United States.
The Imperacer technology produces a 100 to 10,000-fold gain in immunoassay sensitivity by combining well-established enzyme-linked immuno-sorbent assay (Elisa) methodology with the signal amplification power of the polymerase chain reaction (PCR), a molecular biology technique for the enzymatic replication of DNA without using a living organism.
Additionally, the partnership allows AvTech to provide clients worldwide with access to a leading analytical contract research organization (CRO) for routine analysis of clinical and non-clinical samples using the Imperacer technology under good laboratory/manufacturing practice conditions.
"AvTech is a great organisation with a commitment to scientific excellence and regulatory compliance.
"We are excited to work with such an institution," says Ron Wacker, product and service manager at Chimera Biotec.
This innovative technology provides an open technology platform applicable to a broad field of applications and industries including biomarkers, immunogenicity, support for clinical trials, pharmacokinetics and microdosing studies.
Imperacer is recommended if highly sensitive assays, low sample volumes and excellent matrix tolerance are required.
